Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.59 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.50 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69196 | 0.92 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL68274 | 0.91 | CRBN (0.57) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1403665 | 0.88 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1403538 | 0.86 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL26148387 | 0.86 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL62069 | 0.85 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL69525 | 0.84 | CRBN (0.57) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL62335 | 0.84 | CRBN (0.69) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL24819312 | 0.84 | IKZF2 (0.64) | CRBNGSPT1DDB1IKZF3IKZF2 | |
| SCHEMBL60782 | 0.83 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129375-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885GSPT1 2532/4885DDB1 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.